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DYNAMICS OF CANCER RECURRENCE1
By Jasmine Foo and Kevin Leder
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Mutation-induced drug resistance in cancer often causes the fail-
ure of therapies and cancer recurrence, despite an initial tumor reduc-
tion. The timing of such cancer recurrence is governed by a balance
between several factors such as initial tumor size, mutation rates and
growth kinetics of drug-sensitive and resistance cells. To study this
phenomenon we characterize the dynamics of escape from extinction
of a subcritical branching process, where the establishment of a clone
of escape mutants can lead to total population growth after the ini-
tial decline. We derive uniform in-time approximations for the paths
of the escape process and its components, in the limit as the initial
population size tends to infinity and the mutation rate tends to zero.
In addition, two stochastic times important in cancer recurrence will
be characterized: (i) the time at which the total population size first
begins to rebound (i.e., become supercritical) during treatment, and
(ii) the first time at which the resistant cell population begins to
dominate the tumor.
1. Introduction. We consider a situation arising from population genet-
ics, where a population with net negative growth rate can escape certain
extinction via creation of a new mutant type. This scenario arises in a va-
riety of biological and medical applications. In particular, we consider the
following scenario in which a population of drug-sensitive cancer cells is
placed under therapy, leading to a sustained overall decline in tumor size.
However, drug-resistance mutations may arise in the population, conferring
a net positive growth rate to mutated cells and their progeny under ther-
apy. If a mutant arises prior to extinction of the original population and
forms a viable, growing subpopulation, then the population has “escaped”
extinction. These types of escape events due to acquired resistance cause the
failure of many drugs including antibiotics, cancer therapies and anti-viral
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therapies. In the cancer setting, the discovery of new molecularly targeted
therapies has lead to dramatic successes in tumor reduction in the past
decade; however, the majority of these therapies fail due to the development
of drug resistance and subsequent increase in tumor burden and progres-
sion of disease. Examples of targeted therapies for which acquired resistance
exists include erlotinib/gefitinib in EGFR-mutant nonsmall cell lung can-
cer, imatinib, dasatinib or nilotinib in BCR–ABL driven chronic myeloid
leukemia and vemurafenib in BRAF-mutant melanoma.
There has been a significant amount of previous work in the cancer model-
ing literature on understanding the evolutionary dynamics of drug resistance
in cancer. For example, using stochastic processes with a differentiation hi-
erarchy to represent the sensitive and resistant cells of a tumor, Coldman
and Goldie studied the emergence of resistance to one or two drugs [3, 5, 6].
In a different twist, Harnevo and Agur studied drug resistance emerging
due to oncogene amplification using a stochastic branching process model
[7, 8]. Others have used multi-type branching process models to study the
probability of resistance emerging due to point mutations in a variety of situ-
ations, for example, [9, 15]. Komarova and Wodarz also utilized a multi-type
branching model to investigate the general situation in which k mutations
are required to confer resistance against k drugs [12, 13]. Most recently,
in [4] the authors considered an inhomogeneous process wherein the birth
and death rates of both sensitive and resistant cells are dependent upon a
temporally varying drug concentration profile, to accommodate the effects of
pharmacokinetic dynamics as the drug is metabolized over time. The anal-
ysis in most of these works has been focused on calculations of the eventual
probability of developing resistance and the resistant population size, rather
than the variable timing of tumor recurrence.
In addition to work specifically related to mathematical modeling of can-
cer recurrence, we also discuss some mathematical contributions to the study
of extinction paths in subcritical branching processes and the dynamics of
escape in this context. In particular, in [10] Jagers and co-authors considered
large population approximations of “the path to extinction” in Markovian
sub-critical branching processes. In this work they established convergence
of finite dimensional distributions of these paths viewed on the time scale
of extinction. The follow-up work [11] generalized these results to a broader
class of inter-arrival times (i.e., distributions more general than exponen-
tial). Sehl et al. investigated the limiting moments of extinction times of
subcritical branching processes, and used this as a tool for investigating the
effects of various cancer therapies on healthy tissue [20]. Last, Sagitov and
Serra characterized the asymptotic structure for BGW process with escape,
as mutation rate µ→ 0, conditioned on successful escape, which is an im-
portant asymptotic regime in many problems such as the evolution of new
species [19].
DYNAMICS OF CANCER RECURRENCE 3
A typical solid tumor has a density between 107 and 109 cancer cells per
cubic centimeter [14]. Therefore, in this work we are interested in deriving
path approximations of the escape process that are uniform in time, in the
regime of a very large initial population. In the large population limit, it
is tempting to assume that the stochastic model can be approximated by
a purely deterministic model. However, a simple comparison of the mean
behavior of the stochastic model with a deterministic model illustrates that
it is important to consider the stochasticity of the extinction time. Here, we
develop limiting stochastic approximations for the population process that
greatly simplify the population process model while maintaining the stochas-
tic extinction time behavior. Interesting earlier work by Jagers, Sagitov et
al. established convergence of the finite dimensional distributions for the de-
clining sensitive cell populations on the time scale of extinction, leaving open
the question of tightness [10]. In the present work we first construct nearly-
deterministic uniform in time limit approximations to both the declining sen-
sitive population paths as well as the supercritical resistant cell escape paths.
Then, tightness of the joint sensitive and resistant process can be established
as a simple consequence of these approximations, yielding the weak conver-
gence result in simpler fashion than via direct analysis of the joint process.
We then use these approximations to characterize the distribution of
“turnaround times,” at which the total population size switches from sub-
critical to supercritical. In the clinical context, this represents the time at
which progression of disease is observed through serial tumor scans or blood-
work (in leukemias); thus the ability to characterize and predict this time is
of significant prognostic interest. In addition, we characterize the “crossover
time” at which the resistant mutants first overtake the original type in the
population. Estimates of crossover times, and more generally the times at
which certain composition thresholds are reached, are extremely useful in
clinical decision-making. For example, when simultaneous combination ther-
apies are considered, understanding these random times allows for informed
decisions on the optimal time to switch to another therapy and thus “target”
a different subpopulation of cells within the tumor. Figure 1 illustrates these
times in a sample path simulation of the process, in addition to a sample
distribution of turnaround times. Our results are derived in the framework
where the time scale of the processes is sped up by the extinction time of the
original population, a natural time scale since this time represents the max-
imum length of effectiveness of the drug. We restrict our attention to binary
branching processes which are appropriate for modeling cancer cell popu-
lations undergoing binary division; however, these results can be extended
to study more general offspring distributions, and thus may be useful for
studying escape dynamics in viral populations, for instance.
The rest of the paper is organized as follows. In Section 2 we introduce
the model and discuss earlier results in the field. In Section 3 we present
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Fig. 1. Sample simulation of escape dynamics (population size versus time). Dark black
line: total population size of the tumor, labeled grey lines: resistant and sensitive cell
population size. The circle marks the minimum of the total tumor size process (i.e., the
turnaround time), and the point at which red and blue lines cross is the crossover time.
A histogram plotting the distribution of the minimum turnaround time for each sample
path is plotted in green in the background. Parameters: starting population 1000 sensitive,
0 resistant. Net growth rate of sensitive and resistant birth–death processes are −1.0 and
2.0, respectively, and the mutation rate µ= 0.01.
some results on the mean of the resistant cell population at multiples of the
extinction time. In Section 4 we present a path approximation result where
we show that the limit process uniformly approximates both the sensitive
and resistant cell process on the time scale of the extinction time of the
sensitive cells. We determine limiting distributions of the crossover time
when the resistant cell population first becomes dominant, and the random
time of disease progression or the “turnaround” time. In Section 5 we briefly
illustrate an application of these results to studying the time of disease
recurrence due to drug resistance in nonsmall cell lung cancer (NSCLC). In
Section 7 we present the proofs of our main results.
Throughout the paper we use the following standard Landau asymptotic
notation for nonnegative functions f(·) and g(·): f(x) =O(g(x)) means that
f(x)≤ cg(x) for some c ∈ (0,∞), f(x) = Ω(g(x)) if and only if f(x)≥ cg(x),
f(x) = o(g(x)) holds if and only if f(x)/g(x)→ 0 as x→∞ and last, f(x)∼
g(x) holds if and only if f(x)/g(x)→ 1 as x→∞.
2. Model and previous work. In this section we introduce the mathemat-
ical model and notation, and review previous results on related problems.
We start with an initial population of drug sensitive cells with size x. This
population Z0(t) is modeled as a subcritical Markovian binary branching
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process which declines during treatment with net growth rate λ0 < 0, birth
rate r0 and death rate d0; we will also use the notation |λ0|= r. Resistance
mutations arise at rate µxZ0(t), and each of these mutations gives rise to a
supercritical Markovian binary branching process initialized by one mutant
cell with net growth rate λ1 > 0. We set µx = µx
−α for µ> 0 and α ∈ (0,1).
The total population of mutants, which we will call “resistant cells,” is de-
noted Z1(t). These processes are defined on a probability space (Ω,F ,P).
In addition, we define the filtration F it generated by Zj(s), for s ≤ t and
j ≤ i. Note that in this work, unless otherwise stated, the expectation and
probability operators are conditioned on the initial conditions Z0(0) = x and
Z1(0) = 0.
Since the net growth rate of the original population is negative, it will go
extinct eventually with probability 1. We will denote this time of extinction
by Tx, where x denotes the starting population. The following limit theorem
from [17] will prove useful throughout the rest of the paper:
Tx −
1
r
logx⇒
1
r
(η+ log c) as x→∞,(2.1)
where η is a standard Gumbel random variable and c is the Yaglom constant
for Z0. For a binary branching process, the Yaglom constant has the form
(d0 − r0)/r0.
Previously, Jagers and colleagues [10] studied the paths to extinction in a
subcritical Markovian branching process, which we will also call Z0 starting
at size x. They considered the process Z0 on the time scale of the extinc-
tion time and established convergence in finite dimensional distributions as
x→∞.
Theorem 1 (Jagers et al. [10]). For u ∈ [0,1),
xu−1Z0(uTx)
FD
→ c−ue−uη.
Similar results on convergence in finite dimensional distribution of sub-
critical branching processes with more general inter-arrival times were also
shown in [11]. In addition, Kimmel and Wu generalized these results to
consider the case of critical branching processes [22].
3. Mean of Z1(uTx). In this section we examine the growth rate of the
mean of Z1. In addition, we examine a common modeling assumption and
note the importance of considering the tails of the extinction time Tx in
studies of escape dynamics. We will first consider the expected resistant
population at vTx for some v > 0 (and temporarily assume α= 0),
E[Z1(vTx)] = E
[
µTx
∫ v∧1
0
Z0(uTx) exp(λ1Tx(v− u))du
]
.(3.1)
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If we assume that sensitive cells follow a deterministic decay Z0(t) = xe
λ0t
and approximate their extinction time as Tx ≈−
1
λ0
logx, then we can heuris-
tically estimate the expected value as
E[Z1(vTx)] =
µ
r
logx
∫ v∧1
0
x1−ux(λ1/r)(v−u) du
=
µ
r
x1−λ1v/λ0 logx
∫ v∧1
0
x−u(1+λ1/r) du
=
µ
λ1 − λ0
x1+λ1v/r
(
1− exp
[
−(v ∧ 1)
(
1 +
λ1
r
)
logx
])
.
Thus we observe that this expected value is finite for all v > 0.
However, suppose that there is just a single sensitive cell at time t = 0
whose birth rate is r0 = 0, and death rate r. Then, of course, the extinction
time satisfies T1 ∼ exp(r) and by conditioning on this time we have
E[Z1(vTx)] = µ
∫ ∞
0
E[eλ1(vT1−s)1{T1≥v/s}]ds.
Due to the exponential tails of T1 we see that the above integral diverges to
∞ for λ1v ≥ r and we clearly see the importance of the randomness in the
extinction time. The previous result easily applies to models with births and
deaths in the sensitive cell population. In particular, we have the following
proposition.
Proposition 1. Let v > 0 and λ1vr > 1, then for all x, E[Z1(vTx)] is
infinite.
Proof. By conditioning on Z0(s), s > 0 and then applying a change of
measure we can write the integral of interest as
E[Z1(vTx)] = E
[
µTx
∫ v∧1
0
Z0(uTx) exp[λ1Tx(v− u)]du
]
= µ
∫ v∧1
0
∫ ∞
0
teλ1t(v−u)E[Z0(uTx)|Tx ∈ dt]gx(t)dt du,
where gx(t)dt= P(Tx ∈ dt).
Noting the fact that if u < 1 then E[Z0(uTx)|Tx ∈ dt]≥ 1, we can bound
this from below by
E[Z1(vTx)]≥ µ
∫ v∧1
0
∫ ∞
0
teλ1t(v−u)gx(t)dt du
= µ
∫ v∧1
0
(
E[Tx] + λ1(v − u)
∫ ∞
0
eλ1s(v−u)
∫ ∞
s
tgx(t)dt ds
)
du
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≥ µ
∫ v∧1
0
(
E[Tx] + λ1(v − u)
∫ ∞
0
eλ1s(v−u)s
∫ ∞
s
gx(t)dt ds
)
du
≥ µ
∫ v∧1
0
(
E[Tx] + cλ1(v− u)
∫ ∞
t0
eλ1s(v−u)se−rs ds
)
du.
The final inequality is based on the fact that for x≥ 1, P(Tx > s)≥ P(T1 > s)
and the asymptotic result that as t→∞, P(T1 > t)∼ ce
−rt. Considering the
final equation in the previous display, we see that if λ1v > r then for u
sufficiently small, the inner integral diverges to ∞. 
We can easily find the asymptotic growth rate of E[Z1(vTx)] as x→∞.
Based on the previous subsection, we know that this is only meaningful if
we consider v ≤ −λ0/λ1; for simplicity we will just assume that v ≤ 1 and
r = |λ0| ≥ λ1. Earlier heuristic calculations (where we set α = 0) indicate
that the mean of Z1(vTx) grows like x
1+vλ1/r as xր∞. In particular we
have the following theorem.
Theorem 2. Assume that r ≥ λ1, then for v ∈ (0,1] and α ∈ (0,1) we
have that
E[Z1(vTx)]∼ x
1+vλ1/r−α c
λ1v/rµΓ(1− λ1v/r)
λ1 + r
.
We defer the proof of this result to Section 7.
4. Paths of escape. We now establish an approximation theorem for the
paths of the joint process (Z0(uTx),Z1(uTx)). In the large x limit, scaled
versions of these paths can be approximated uniformly in time by a simple
stochastic process whose only source of randomness arises from the stochas-
ticity of the limit theorem for the extinction time.
Before beginning, we first establish some notation. We will work with
scaled versions of the sensitive and resistant populations sped up in time.
Let us define sx(t) =
1
r logx+ t. For u ∈ [0,1] and t ∈R, define
Zx0 (usx(t)) = x
u−1Z0
(
u
(
1
r
logx+ t
))
,
(4.1)
Zx1 (usx(t)) = x
−λ1u/r−1+αZ1
(
u
(
1
r
logx+ t
))
.
Throughout the rest of the paper, the superscript x will denote scaling by
the appropriate function of x. For ease of notation we introduce the following
notation:
φx0(u, t) = EZ
x
0 (usx(t)) = e
λ0ut,
φx1(u, t) = EZ
x
1 (usx(t)) =
µeλ1ut
λ1 − λ0
(1− e(λ0−λ1)utx(λ0−λ1)u/r).
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In addition, we will sometimes need to work with the population processes
sped up in time but not scaled in space, which are defined for Zi(usx(t)),
for i= 0,1 and their means are denoted by
φi(u, t) = EZi(usx(t)).
In the following, we establish the approximation result by first showing
that for any t ∈R we can approximate the scaled joint process by its mean
uniformly in u. This is done by martingale arguments and showing rele-
vant second moments are uniformly bounded in x. We then prove that this
approximation is uniform for t in compact sets, and that one can approxi-
mate (Z0(uTx),Z1(uTx)) uniformly in time by (φ0(u,Tx−
1
r logx), φ1(u,Tx−
1
r logx)), where the previous formula is interpreted as the mean functions
φxi evaluated at the random parameter Tx −
1
r logx. We begin with a result
on the moments of Z0 and Z1.
Lemma 1. Let Z˜1 be a binary branching process starting from size one
with birth rate r1 and death rate d1, then for 0< s< sx(t),
(i)
E[Z1(sx(t))
2] =
µ2
x2α
∫ sx(t)
0
∫ sx(t)
0
E[Z0(s)Z0(y)]e
λ1(sx(t)−s)eλ1(sx(t)−y) dsdy
+
µ
xα
∫ sx(t)
0
EZ0(s)E[Z˜1(sx(t)− s)
2]ds.
(ii)
E[Z0(s)Z1(sx(t))] =
µ
xα
∫ sx(t)
0
E[Z0(y)Z0(s)]e
λ1(sx(t)−y) dy.
(iii)
Var[Z1(sx(t))] =
µ2
x2α
∫ sx(t)
0
∫ sx(t)
0
Cov(Z0(s),Z0(y))e
λ1(2sx(t)−(s+y)) dsdy
+
µ
xα
∫ sx(t)
0
EZ0(s)E[Z˜1(sx(t)− s)
2]ds.
The proof of this result can be found in Section 7.
Lemma 1 allows us to establish the following result via the Doob’s maxi-
mal inequality.
Lemma 2. For a ∈ (0,1), ε > 0 and t ∈R,
(i)
lim
x→∞
P
(
sup
u∈[0,a]
|Zx0 (usx(t))− φ
x
0(u, t)|> ε
)
= 0.
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(ii)
lim
x→∞
P
(
sup
u∈[0,1]
|Zx1 (usx(t))− φ
x
1(u, t)|> ε
)
= 0.
The proof of this result can be found in Section 7.
We can strengthen Lemma 2 by showing the convergence above is in fact
uniform for t in a compact set.
Lemma 3. For a ∈ (0,1), ε > 0 and M > 0,
(i)
lim
x→∞
P
(
sup
t∈[−M,M ]
sup
u∈[0,a]
|Zx0 (usx(t))− φ
x
0(u, t)|> ε
)
= 0.
(ii)
lim
x→∞
P
(
sup
t∈[−M,M ]
sup
u∈[0,1]
|Zx1 (usx(t))− φ
x
1(u, t)|> ε
)
= 0.
The result is established by showing that the probabilities in the statement
of Lemma 2 are monotone in the parameter t. Again, we defer the full proof
until Section 7.
Using this uniform approximation result, we establish the following theo-
rem for the process paths evaluated at multiples of the Z0 extinction time.
Theorem 3. For a < 1, ε > 0 and µx = µx
−α, where α ∈ (0,1),
(i)
lim
x→∞
P
(
sup
u∈[0,a]
xu−1
∣∣∣∣Z0(uTx)− φ0
(
u,Tx −
1
r
logx
)∣∣∣∣> ε
)
= 0.
(ii)
lim
x→∞
P
(
sup
u∈[0,1]
xα−uλ1/r−1
∣∣∣∣Z1(uTx)− φ1
(
u,Tx −
1
r
logx
)∣∣∣∣> ε
)
= 0.
Proof. This result now follows directly from Lemma 3 and the result
in (2.1). 
We define the following stochastic processes: if u ∈ [0,1],
ψ0(u) = e
−u(η+log c),
ψ1(u) =
{ µ
λ1 + r
e(λ1u/r)(η+log c), u > 0,
0, u= 0.
These processes represent the limits of our scaled population processes. How-
ever, note that ψ1 is not right-continuous at 0 and therefore it is not possible
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to establish that the scaled population processes are tight on an interval of
the form [0, b] in the standard Skorokhod topology. This is a result of the
massive influx of mutations near t= 0 in the unscaled process.
Next, we utilize Theorem 3 to establish weak convergence in the Sko-
rokhod sense of the joint process.
Corollary 4. For α ∈ [0,1) and 0< a< b < 1 the joint process
{(xu−1Z0(uTx), x
α−λ1u/r−1Z1(uTx)), u∈ [a, b]}⇒ {(ψ0(u), ψ1(u)), u ∈ [a, b]}
as x→∞ in the standard Skorokhod topology, D([a, b]).
Proof. For ease of notation, throughout this proof we will use the fol-
lowing notation:
φx(u) =
(
φx0
(
u,Tx −
1
r
logx
)
, φx1
(
u,Tx −
1
r
logx
))
.
Clearly, from the result in Theorem 3 it suffices to prove that as x→∞(
φx0
(
·, Tx −
1
r
logx
)
, φx1
(
·, Tx −
1
r
logx
))
⇒ (ψ0(·), ψ(·))
in D([a, b]). We will carry this out via Theorem 13.3 of [1]. First, we observe
that convergence in finite dimensional distributions follows from (2.1) and
the continuous mapping theorem. Thus it only remains to establish tightness.
Since our limit functions are continuous at u = a and u = b, it suffices to
establish that for every ε > 0
lim
δ→0
lim sup
x→∞
P(ω′′x(δ)≥ ε) = 0,(4.2)
where
ω′′x(δ)
.
= sup{‖φx(u)−φx(u1)‖∧‖φ
x(u2)−φ
x(u)‖ :u1 ≤ u≤ u2, u2−u1 ≤ δ}
and ‖x‖ ≡ |x1|+ |x2|. From the mean value theorem there exists a constant
C such that for u < v ∈ [a, b]
‖φx(u)−φx(v)‖ ≤C(v− u)
∣∣∣∣Tx − 1r logx
∣∣∣∣eλ1v|Tx−(1/r) logx|
≤C(v− u)e(λ1+1)b|Tx−(1/r) logx|.
Thus, if ω′′x(δ)≥ ε, then
Cδe(λ1+1)b|Tx−(1/r) logx| ≥ ε,
and therefore,
P(ω′′x(δ)≥ ε)≤ P
(∣∣∣∣Tx − 1r logx
∣∣∣∣≥ b(λ+1) log(ε/δ)
)
.
Condition (4.2) then follows by taking the limit as x→∞ [using (2.1)] and
then sending δ to 0. 
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4.1. Crossover time. We define the following stochastic time:
ξ ≡ inf{t > 0|Z1(t)≥ Z0(t)},
which we refer to as the “crossover” time, since it is the first time at which
the Z0 and Z1 paths cross, and represents roughly the time at which the Z1
or resistant cell population begins to dominate the tumor. In this section
we investigate, using the limit theorems proven in the previous section, the
distribution of the crossover time scaled by Tx. First we utilize the crossover
time of the limit processes to obtain an estimate of this time. In particular,
we define u˜ to be the solution to
φ0
(
u˜, Tx −
1
r
logx
)
= φ1
(
u˜, Tx −
1
r
logx
)
.
We obtain
u˜=
log(µ+ (λ1 + r)x
α)− logµ
Tx(λ1 + r)
and establish the following result.
Theorem 5. The estimate u˜ and the scaled crossover time, ξ/Tx, con-
verge to each other in probability as x→∞, that is, for all ε > 0,
P
(∣∣∣∣ ξTx − u˜
∣∣∣∣> ε
)
→ 0 as x→∞.
See Section 7 for the proof of this result, which follows as an application
of Theorem 3.
4.2. Turnaround time: Progression of disease. In this section we char-
acterize the time at which the total tumor population stops declining and
starts increasing. Define the following set of random times associated with
the unscaled escape process:
τ = argmin
t≥0
{Z0(t) +Z1(t)}.
Using the sample path approximations, we can approximate this set of times,
rescaled by the extinction time Tx, as the random variable
u∗ ≡
log(r/(λ1µ)) + log(x
α(λ1 + r)− µ)
(λ1 + r)Tx
.(4.3)
This corresponds to the time at which the approximated path of the total
population size has derivative zero. Looking at the highest order terms in
(4.3), we see that for large x,
u∗ ≈
αr
λ1 + r
.(4.4)
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Thus a higher mutation rate, or smaller α, leads to a quicker turnaround time
(relative to the extinction time). In addition, as the decay rate r increases,
the time of progression relative to the time of extinction increases.
Throughout this section we work with the sped-up but unscaled joint
population processes, Zi(usx(t)). For simplicity, write the sum of the mean
of Z0 and Z1 as
fx,t(u)≡ EZ0(usx(t)) +EZ1(usx(t))
= xeλ0u((1/r) logx+t)
(
1−
µ
xα(λ1 + r)
)
+
x1−αµeλ1u((1/r) logx+t)
λ1 + r
.
We will first show that with high probability, the critical point of fx,t,
u∗(t)≡
log(r/(λ1µ)) + log(x
α(λ1 + r)− µ)
(λ1 + r)((1/r) logx+ t)
(4.5)
is close to the minimum of Z0(usx(t)) +Z1(usx(t)). We then establish that
this statement is in fact true uniformly for t in compact sets, and that τ/Tx
is well approximated by u∗.
Since u∗(t) is a critical point of fx,t we have the following representation
that will be useful:
fx,t(u
∗(t)) = xeλ0u
∗(t)((1/r) log x+t)
(
1−
µ
xα(λ1 + r)
)(
1 +
r
λ1
)
,
and
fx,t(u
∗(t) + y) = xeλ0u
∗(t)((1/r) log x+t)
(
1−
µ
xα(λ1 + r)
)
×
(
eλ0y((1/r) log x+t) +
r
λ1
eλ1y((1/r) log x+t)
)
.
Therefore,
fx,t(u
∗(t) + y) = fx,t(u
∗(t))
[(
λ1
λ1 + r
)(
x−yeλ0yt +
r
λ1
xλ1y/reλ1yt
)]
.(4.6)
With this “steepness” at the minimum property we can establish that with
high probability (for x large) the minimum of the total population is achieved
at u∗(t).
Lemma 4. For ε > 0,
P
(
τ
(1/r) logx+ t
∩ [u∗(t)− ε,u∗(t) + ε]c 6=∅
)
→ 0
as x→∞.
The proof of this result is deferred to Section 7.
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Similar to the approximation result in Lemma 2, it is then possible to
establish that an analogous result holds uniformly for t in compact sets.
Lemma 5. For ε > 0 and a constant M > 0,
(i)
P
(
sup
t∈[−M,M ]
inf
u∈[0,u∗(t)−ε)
Z0(usx(t))+Z1(usx(t))<Z0(u
∗Tx)+Z1(u
∗Tx)
)
→ 0.
(ii)
P
(
sup
t∈[−M,M ]
inf
u∈[0,u∗(t)+ε)
Z0(usx(t))+Z1(usx(t))<Z0(u
∗Tx)+Z1(u
∗Tx)
)
→ 0
as x→∞.
See Section 7 for details of the proof.
We can now establish that the turnaround time of the scaled process τ
normalized by the extinction time Tx converges in probability to u
∗.
Theorem 6. For ε > 0,
P
(
τ
Tx
∩ [u∗ − ε,u∗ + ε]c 6=∅
)
→ 0
as x→∞.
Proof. Using similar techniques as in the proof of Theorem 3, the result
follows easily from the previous two lemmas. 
In Figure 2 we compare the sample probability density function of τ/Tx
from simulations of the (Z0,Z1) process with the theoretical PDF of u
∗. It
is observed that even with an initial starting population of size x= 100,000,
the comparisons are favorable. Thus, in the application of interest where x is
on the order of 106 cells or greater, we expect these limiting approximations
to be of use.
5. An example: Recurrence dynamics in nonsmall cell lung cancer. In
this section we apply the results to a simple model of drug resistance in
nonsmall cell lung cancer (NSCLC). Nonsmall cell lung cancer is a disease in
which malignant cells form in the tissues of the lung; it is the most common
type of lung cancer, which causes over 150,000 deaths per year in the U.S. In
recent years, a new class of targeted anti-cancer drugs called tyrosine kinase
inhibitors has been developed. These inhibitors target molecules specifically
within cancer cells and inhibit key signaling pathways such as the epidermal
growth factor receptor (EGFR). Two such inhibitors, erlotinib and gefitinib,
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Fig. 2. Sample PDF of τ/Tx from simulation of (Z0,Z1) process compared with theo-
retical PDF of u∗, for initial size x= 100,000 and two parameter sets. Top: x= 100,000,
r0 = 1.0, d0 = 1.5, r1 = 2.0, d1 = 1.0, µ= 0.01. Bottom: x= 100,000, r0 = 1.0, d0 = 1.75,
r1 = 2.0, d1 = 1.0, µ= 0.01.
have been shown to be extremely successful in reducing tumor burden in
a substantial subset of NSCLC patients. However, point mutations in the
binding site of the drug have been identified that confer resistance to both
therapies, and thus lead to recurrence or progression of the disease.
In previous work [2] we characterized the in vitro growth rates of a pair
of human NSCLC cell lines which were sensitive or resistant to the drug
erlotinib (see Figure 3). Here we utilize this experimental growth kinetic
data and apply our results on turnaround time distribution to study the
properties of the time of disease progression. In particular, for a series of
drug concentrations we characterize the distribution of the random time u∗,
using the experimental data to ascertain r0, d0, r1 and d1. In addition, we
use known estimates of the biological parameter µx ≈ 10
−8, which corre-
sponds to the mutation probability per cell division per base pair in the
genome [16, 21]. We can then apply our estimates of the turnaround time
distribution to study how the time until progression varies as a function of
drug concentration. These distributions of u∗ are helpful in predicting the
likely success of the therapy. In particular, u∗ indicates the fraction of the
total time that the drug is effective (Tx) at which disease progression occurs.
If the distribution of u∗ for a particular drug at a specific concentration has
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Fig. 3. Growth and death rate data (hours−1) for erlotinib-sensitive (PC-9) and er-
lotinib-resistant NSCLC cells as a function of drug concentration (data published in [2]).
most of its mass bounded far below 1, the chance that the sensitive cell drug
population is eradicated by the time of progression is extremely low. On the
other hand, drugs whose profiles which place most of the u∗ distribution’s
mass closer to 1 have better prospects of eliminating the tumor. In Figure 4
Fig. 4. Distributions of the turnaround time, u∗, for a NSCLC tumor with initially 109
sensitive cells, treated with erlotinib at 1 µM (top left), 3 µM (top right), 5 µM (bottom
left) and 10 µM (bottom right).
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we plot the u∗ distribution for a NSCLC tumor starting with 109 sensitive
cells treated with erlotinib at various concentrations. Note that the current
standard of care, the FDA approved dose elicits a concentration of 3 µM
in the plasma which corresponds to the upper right plot. As the drug con-
centration increases, the distribution of u∗ moves accordingly to the right;
however, even at the highest concentration the majority of the mass is still
bounded well below 1 which indicates likely failure of the therapy. In clinical
observations, following an initial response in terms of tumor reduction, 100
percent of patients develop resistance usually within 24 months of starting
treatment [18].
One major clinical question in NSCLC treatment today is: once the dis-
ease has progressed and the tumor size begins to increase, what course of
therapy is optimal? In particular, should the drug be withdrawn or should
the patient be kept on erlotinib or gefitinib? If drug is maintained, how long
should it be administered beyond progression? Here, estimates of the u∗
distribution can be of use. We note that τ is a clinically observable quan-
tity since it represents the time until disease progression from the start of
treatment. Once τ is observed, using Theorem 6 and the approximation in
(4.4) we can approximate Tx, which represents the time at which the en-
tire drug-sensitive population is eradicated. This gives a clear endpoint, Tx
beyond which erlotinib therapy is unwarranted. Furthermore, we can eas-
ily obtain the distribution of the population size of resistant cells at this
time Z1(Tx) to estimate the projected resistant tumor size at the time the
sensitive cells are eradicated. This information aids in determining whether
erlotinib treatment should be maintained until Tx or a switch to alternative
therapy should be made prior to Tx.
6. Summary. In this work we have considered the stochastic dynamics of
escape from extinction in a binary branching process model. By considering
the large starting population limit, we approximate the birth–death process
with a simpler stochastic process whose only randomness is inherited from
the weak limit of the extinction time. Using this limit, we approximate the
distribution of the time until the total population begins to increase, and
the time at which the escape mutants first begin to dominate the popula-
tion. One of many possible future extensions is to consider the problems in
this paper in a non-Markovian setting, that is, nonexponential distribution
between events. This work contributes to a growing body of literature con-
cerned with the mathematical understanding of cancer evolution, as well as
to the general understanding of extinction and escape paths in branching
process models. In future work we examine the setting α = 1, where O(1)
mutations arise before extinction and escape from extinction is not assured
in the large x limit.
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7. Proof of main results.
7.1. Proof of Theorem 2. We first establish the scaling of the mean for
large initial population x.
By conditioning on the path of Z0 until Tx we get the formula (3.1);
performing a change of measure and flipping the order of integration (by
Tonelli’s theorem) we see
E[Z1(vTx)] = µxE
[∫ ∞
0
1{Tx≥y/v}Z0(y) exp(λ1(vTx − y))dy
]
= µx
∫ ∞
0
E[1{Tx≥y/v}Z0(y) exp(λ1(vTx − y))]dy
= µx
∫ ∞
0
∫ ∞
y/v
∞∑
n=1
neλ1(vt−y)P(Tx ∈ dt|Z0(y) = n)P(Z0(y) = n)dy.
Note that P(Tx ∈ dt|Z0(y) = n) = gn(t − y)dt, where gn is the density of
the extinction time for a population starting from a population of size n,
and can be written as gn(t) = n(G(t))
n−1g(t), where g is the density of the
extinction time for a population starting from a single cell, and G is the
c.d.f. Therefore, upon rearranging the order of integration we get that
E[Z1(vTx)]
= µx
∫ ∞
0
∫ ∞
y/v
eλ1(vt−y)g(t− y)
(
∞∑
n=1
n2(G(t− y))n−1P(Z0(y) = n)
)
dt dy.
Next define
Fx(s, t) = E[s
Z0(t)] and F (s, t) = E[sZ0(t)|Z0(0) = 1,Z1(0) = 0],
and observe that due to the independence of the branching structure Fx(s, t) =
(F (s, t))x. Therefore,
∞∑
n=1
n2sn−1P(Z0(t) = n)
= s
∂2
∂s2
Fx(s, t) +
∂
∂s
Fx(s, t)
(7.1)
= sx(F (s, t))x−1
∂2
∂s2
F (s, t) + sx(x− 1)(F (s, t))x−2
(
∂
∂s
F (s, t)
)2
+ x(F (s, t))x−1
∂
∂s
F (s, t).
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For ease of notation we will simply write ∂∂sF (s, t) = F
′(s, t). Using (7.1) we
obtain
E[Z1(vTx)]
= xµx
∫ ∞
0
∫ ∞
y/v
eλ1(vt−y)g(t− y)F (G(t− y), y)x−2
× [(x− 1)G(t− y)F ′(G(t− y), y)2
+G(t− y)F (G(t− y), y)F ′′(G(t− y), y)
+ F (G(t− y), y)F ′(G(t− y), y)]dy dt.
This expression can be analyzed using techniques from [10]. In particular, if
we introduce the change of variable
t=
1
r
(z + log cx) = zx,
observe that
eλ1(vzx−y) = eλ1(vz/r−y)(cx)λ1v/r.
After the change of variables we have
E[Z1(vTx)] = I1(x, v) + I2(x, v),
where
I1(x, v) =
x(x− 1)(cx)λ1v/rµx
r
∫ ∞
0
∫
ry/v−log cx
Φ1(z, y)dz dy,
I2(x, v) =
x(cx)λ1v/rµx
r
∫ ∞
0
∫ ∞
ry/v−log cx
Φ2(z, y)dz dy
and
Φ1(z, y) = e
λ1(vz/r−y)g(zx − y)G(zx − y)
× (F (G(zx − y), y))
x−2(F ′(G(zx − y), y))
2,
Φ2(z, y) = e
λ1(vz/r−y)g(zx − y)(F (G(zx − y), y))
x−1
× [G(zx − y)F
′′(G(zx − y), y) +F
′(G(zx − y), y)].
We will now establish that for v ∈ (0,1], xα−1−λ1v/rI1(x, v) = I˜1(x, v)→
I1(v) and x
α−1−λ1v/rI2(x, v) = I˜2(x, v) → 0 as x→∞. The integrand of
I˜1(x, v) is
fx(z, y) = c0xg(zx − y)G(zx − y)
× (F (G(zx − y), y))
x−2(F ′(G(zx − y), y))
2eλ1(vz/r−y),
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where c0 = µc
λ1v/r/r. From [10] we know that as z→∞, g(z)∼ rce−rz, and
therefore
g(zx − y)∼
r
x
erye−z(7.2)
as x→∞. Next note that there exists a ξx ∈ (G(zx − y),1) such that
F ′(G(zx − y), y) = F
′(1, y) + (1−G(zx − y))F
′′(ξx, y)
= e−ry +O(1−G(zx − y)),
and therefore
F ′(G(zx − y), y)∼ e
−ry.(7.3)
Last, observe that
F (G(zx − y), y) = 1+ e
−ry(G(zx − y)− 1) +O(G(zx − y)− 1)
2,
and therefore
logF (G(zx − y), y) =−(1−G(zx − y))e
−ry +O(G(zx − y)− 1)
2.
Observe that
1−G(zx − y)∼
erye−z
x
,
which gives that
(F (G(zx − y), y))
x−2 ∼ exp[−e−z].(7.4)
Combining (7.2), (7.3) and (7.4) we see that
lim
x→∞
fx(z, y) = c1e
−z(1−(λ1/r)v)e−y(r+λ1) exp[−e−z],(7.5)
where c1 = rc0. In order to evaluate the limit of I˜1 it thus remains to show
that the limit can be passed inside the integral; this will be done by finding
an integrable function h such that fx(z, y) ≤ h(z, y). First note that since
G(z)≤ 1 and F ′(s, t)≤E1Z0(t) = e
−rt, we have
fx(z, y)≤ c0xe
λ1(vz/r−y)g(zx − y)(F (G(zx − y), y))
x−2e−2ry.
Then observe that there exists a constant k1 such that
g(zx − y)≤ k1e
−r(zx−y) =
k2
x
e−zery.(7.6)
Since logx≤ x− 1 we have
(F (G(zx − y), y))
x−2 = exp[(x− 2) logF (G(zx − y), y)]
≤ exp[−(x− 2)(1−F (G(zx − y), y))].
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Using results from the proofs of Proposition 1 and Lemma 1 of [10], we can
establish that
1−F (G(zx − y), y)≥
e−z
x
.(7.7)
Based on (7.6) and (7.7) we see that we can use the dominating function
h(z, y) = k3e
λ1(vz/r−y)e−ze−ry exp[−k2e
−z].
With this result we see that
lim
x→∞
I˜1(x, v) = c0
∫ ∞
0
∫ ∞
−∞
lim
x→∞
fx(z, y)dz dy
= c1
∫ ∞
0
∫ ∞
−∞
eλ1(vz/r−y)e−yre−z exp[−e−z]dz dy
=
µcλ1v/rΓ(1− λ1v/r)
(λ1 + r)
.
We now consider I˜2. First observe that for (s, t) ∈ [0,1]× [0,∞) there exists
finite k4 such that F
′(s, t)≤ k4 and F
′′(s, t)≤ k4 and, of course, F (s, t)≤ 1.
Therefore, if we consider I˜2 in terms of the original variables, there exists a
finite constant k5 such that
I˜2(x, v)≤ k5x
−vλ1/r
∫ ∞
0
∫ ∞
y/v
eλ1(vt−y)g(t− y)dt dy
= k5x
−vλ1/r
∫ ∞
0
∫ ∞
y(1/v−1)
e−λ1yg(s)eλ1v(s+y) dsdy = k6x
−vλ1/r,
where the first equality follows by using the change of variable s = t − y.
Thus I˜2(x, v)→ 0 as x→∞ for v ∈ (0,1].
7.2. Proof of Lemma 1. We will start by establishing item (ii). Define
F0∞ to be the sigma algebra generated by the wave 0 population until their
eventual extinction, then
E[Z1(sx(t))|F
0
∞] = µx
∫ sx(t)
0
Z0(y)e
λ1(sx(t)−y) dy
and therefore
E[Z0(s)Z1(sx(t))] = e
λ1sx(t)µx
∫ sx(t)
0
E[Z0(y)Z0(s)]e
−λ1y dy.
Now we establish the second moment result, item (i). For simplicity we
evaluate E[Z1(t)] for a positive t. For ease of notation we will use the follow-
ing E˜[·] = E[·|F0∞]. Consider a partition of [0, t], 0<∆< 2∆< · · ·< t, where
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∆= t/m for a large integer m. Then we can write
E[Z1(t)
2|F0∞] = E˜
(
m∑
j=0
Nj∑
k=1
Bj,k(t− τj,k)
)2
=
m∑
j=0
E˜
( Nj∑
k=1
Bj,k(t− τj,k)
)2
+
m∑
j=0
∑
ℓ 6=j
E˜
( Nj∑
k=1
Bj,k(t− τj,k)
)
E˜
(
Nℓ∑
k=1
Bℓ,k(t− τℓ,k)
)
,
where Nj is the number of type-1 mutants created in [j∆, (j +1)∆), {Bj,k}
is a collection of i.i.d binary birth–death processes with birth rate a1 and
death rate d1 and τj,k is the time of creation for the kth mutant created in
[j∆, (j+1)∆). In the previous display we have used the independence of the
branching process to derive the second equality. For 0≤ j ≤m,
ENj =∆µxZ0(j∆)+ o(∆),
EN2j =∆µxZ0(j∆)(1 +∆µxZ0(j∆)) + o(∆).
Therefore,
E˜
( Nj∑
k=1
Bj,k(t− τj,k)
)2
= E˜NjE˜B(t− τj)
2 + E˜[Nj(Nj − 1)](E˜B(t− τj))
2
=∆µxZ0(j∆)E˜B(t− τj)
2 +O(∆2)
= ∆µxZ0(j∆)
(
2r1
λ1
e2λ1(t−τj ) −
r1 + d1
λ1
eλ1(t−τj)
)
+O(∆2)
and
E˜
(
Nℓ∑
k=1
Bℓ,k(t− τℓ,k)
)
=∆µxZ0(j∆)E˜B(t− τj)
= ∆µxZ0(j∆)e
λ1(t−τj ).
Using the previous two expressions we get
E˜[Z1(t)
2] = ∆µx
m∑
j=0
Z0(j∆)
(
2r1
λ1
e2λ1(t−τj ) −
r1 + d1
λ1
eλ1(t−τj )
)
+ (µx∆)
2
m∑
j=0
m∑
ℓ=0,ℓ 6=j
Z0(j∆)Z0(ℓ∆)e
λ1(t−τj)eλ1(t−τℓ).
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Sending ∆→ 0, integrating over Z0 and replacing t with
1
r logx+ t gives us
the desired formula for item (i).
Item (iii) follows immediately from item (i).
7.3. Proof of Lemma 2. We will prove the more difficult second state-
ment first. We observe that it suffices to prove that as x→∞,
P
(
sup
u∈[0,1]
e−λ1ut|Zx1 (usx(t))− φ
x
1(u, t)|> e
−λ1tε
)
→ 0.
Next observe that
e−λ1ut
x−α+1+λ1u/r
(Z1(usx(t))− φ1(u, t))
=
(
e−λ1ut
x1+λ1u/r
Z1(usx(t))−
µ
x1+α
∫ usx(t)
0
Z0(s)e
−λ1s ds
)
xα
+
µ
x
∫ usx(t)
0
(Z0(s)− xe
λ0s)e−λ1s ds,
and therefore
P
(
sup
u∈[0,1]
e−λ1ut|Zx1 (usx(t))− φ
x
1(u, t)|> e
−λ1tε
)
≤ P
(
sup
u∈[0,1]
xα
∣∣∣∣ e−λ1utx1+λ1u/rZ1(usx(t))− µx1+α
∫ usx(t)
0
Z0(s)e
−λ1s ds
∣∣∣∣> ε/2
)
+ P
(
sup
u∈[0,1]
µ
x
∫ usx(t)
0
|Z0(s)− xe
λ0s|e−λ1s ds > ε/2
)
.
However, we can observe that the process considered in the second expres-
sion in the sum is monotonic in u, and the process considered in the first
expression is a martingale in u, which allows us to arrive at the following
simpler inequality:
P
(
sup
u∈[0,1]
e−λ1ut|Zx1 (usx(t))− φ
x
1(u, t)|> e
−λ1tε
)
≤
4x2α
ε2
E
[(
e−λ1t
xλ1/r+1
Z1(sx(t))−
µ
x1+α
∫ sx(t)
0
Z0(s)e
−λ1s ds
)2]
(7.8)
+ P
(
µ
x
∫ sx(t)
0
|Z0(s)− xe
λ0s|e−λ1s ds > ε/2
)
.
Consider the latter quantity first, where it suffices to show that as x→∞,
µ
x
∫ sx(t)
0
E[|Z0(s)− xe
λ0s|]e−λ1s ds→ 0.
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Next observe that
Var(Z0(s)) = x
(
r0 + d0
λ0
)
(e2λ0s − eλ0s).
It follows from the Cauchy–Schwarz inequality that
µ
x
∫ sx(t)
0
E[|Z0(s)− xe
λ0s|]e−λ1s ds=O(x−1/2).
Moving on to the first term in (7.8),
x2αE
[(
e−λ1t
xλ1/r+1
Z1(sx(t))−
µ
x1+α
∫ sx(t)
0
Z0(s)e
−λ1s ds
)2]
=
(
e−λ1txα
x1+λ1/r
)2
E[Z1(sx(t))
2]
(7.9)
− 2
x2αµe−λ1t
x2+λ1/r+α
∫ sx(t)
0
e−λ1sE[Z0(s)Z1(sx(t))]ds
+
(
µ
x
)2 ∫ sx(t)
0
∫ sx(t)
0
E[Z0(s)Z0(y)]e
−λ1se−λ1y dsdy.
Using Lemma 1 we see that (7.9) can be written as
2r1x
α−1µ
λ1
∫ sx(t)
0
es(λ0−2λ1) ds−
(r1 + d1)µe
−λ1t
λ1x1−α+λ1/r
∫ sx(t)
0
es(λ0−λ1) ds=O(xα−1),
thus establishing the result (ii).
We now move on to the proof of item (i). First observe that
sup
u∈[0,a]
|Zx0 (usx(t))− φ
x
0(u, t)| ≤ e
−λ0at− sup
u∈[0,a]
e−λ0ut|Zx0 (usx(t))− φ
x
0(u, t)|,
where t− =−min(t,0). We will show that as x→∞,
P
(
sup
u∈[0,a]
|e−λ0utZx0 (usx(t))− 1| ≥ εe
λ0at−
)
→ 0.
Observe that e−λ0utxu−1Z0(usx(t)) − 1 is a martingale with respect to u.
Therefore, it suffices to show that as x→∞,
E[e−λ0atZx0 (asx(t))− 1]
2 = x2a−1e−2aλ0tVar1Z0(asx(t))→ 0,
where Var1Z0(t) represents the variance of Z0(t) starting with an initial
population size 1. The previous expression reduces to
xa−1e−aλ0t(x−ae−λ0at − 1)(r0 + d0)/λ0,
and since we have assumed that a < 1, the result is established.
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7.4. Proof of Lemma 3. Throughout the proof assume that x > erM . We
first establish the result for the Z1 population by showing the following
monotonicity property in t:
sup
u∈[0,1]
∣∣∣∣Zx1
(
u
(
1
r
logx+ t0
))
− φx1(u, t0)
∣∣∣∣
(7.10)
≤ sup
u∈[0,1]
∣∣∣∣Zx1
(
u
(
1
r
logx+ t1
))
− φx1(u, t1)
∣∣∣∣
for t0 ≤ t1. For any u ∈ [0,1] set
u¯≡
u((1/r) logx+ t0)
(1/r) logx+ t1
,
which, of course, implies that u¯(1r logx+ t1) = u(
1
r logx+ t0). In addition,
observe that u¯≤ u and thus x−λ1u/r ≤ x−λ1u¯/r. Therefore,
x−λ1u/r
∣∣∣∣Z1
(
u
(
1
r
logx+ t0
))
− φ1(u, t0)
∣∣∣∣
≤ x−λ1u¯/r
∣∣∣∣Z1
(
u¯
(
1
r
logx+ t1
))
− φ1(u¯, t1)
∣∣∣∣.
Since u ∈ [0,1] was arbitrary we have that
sup
t∈[−M,M ]
sup
u∈[0,1]
xα−1−λ1u/r|Z1(usx(t))− φ1(u, t)|
≤ sup
u∈[0,1]
xα−1−λ1u/r
∣∣∣∣Z1
(
u
(
1
r
logx+M
))
− φ1(u,M)
∣∣∣∣.
Result (ii) now follows by an application of Lemma 2.
The proof of result (i) will follow a similar approach. In particular, for
t≤M and u ∈ [0, a], define
uˆ= u
(
(1/r) logx+ t
(1/r) logx+M
)
.
Notice that
u− uˆ= u
(
M − t
(1/r) logx+M
)
≤ a
(
M − t
(1/r) logx+M
)
= n(x,M).
Using the definition of n(x,M) it follows that n(x,M) logx≤ 2arM which
implies that xu−uˆ ≤ e2arM . Based on the definition of uˆ and the upper bound
on xu−uˆ
xu|Z0(usx(t))− φ0(u, t)|
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= xu−uˆxuˆ
∣∣∣∣Zx0
(
uˆ
(
1
r
logx+M
))
− φ0(u˜,M)
∣∣∣∣
≤ e2arMxuˆ
∣∣∣∣Z0
(
uˆ
(
1
r
logx+M
))
− φ0(uˆ,M)
∣∣∣∣.
Since the previous inequality holds for any u, we know that for any t ∈
[−M,M ],
sup
u∈[0,a]
xu|Z0(usx(t))− φ0(u, t)|
≤ e2arM sup
u∈[0,a]
xu
∣∣∣∣Z0
(
u
(
1
r
logx+M
))
− φ0(u,M)
∣∣∣∣.
Thus the result of (i) is established by using the result of Lemma 2 for t=M .
7.5. Proof of Theorem 5. First we prove that P(ξ/Tx ≤ u˜ − ǫ)→ 0 as
x→∞. In particular, recall that
φ0(u, t) = x
1−ueλ0ut,
φ1(u, t) =
µx1−α+λ1u/reλ1ut
λ1 + r
(1− eu(λ0−λ1)tx(λ0−λ1)u/r).
Then let us utilize the notation d(Tx)≡ Tx −
1
r logx to represent the devia-
tion of Tx from its scaling,
P
(
sup
u≤u˜−ǫ
(Z1(uTx)−Z0(uTx))> 0
)
≤ P
(
sup
u≤u˜−ǫ
xu−1(Z1(uTx)− φ1(u,d(Tx)) + (φ1(u,d(Tx))− φ0(u,d(Tx)))
+ (φ0(u,d(Tx))−Z
x
0 (uTx))> 0, |d(Tx)| ≤
1
r
logx
)
+ P
(
|d(Tx)|>
1
r
logx
)
≤ P
(
sup
u≤u˜−ǫ
xu−1(Z1(uTx)− φ1(u,d(Tx)))
+ sup
u≤u˜−ǫ
xu−1(φ1(u,d(Tx))− φ0(u,d(Tx)))
+ sup
u≤u˜−ǫ
xu−1(φ0(u,d(Tx))−Z
x
0 (uTx))> 0, |d(Tx)| ≤
1
r
logx
)
+ P
(
|d(Tx)|>
1
r
logx
)
.
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Clearly P(|d(Tx)| >
1
r logx)→ 0 as x→∞, and it thus remains to analyze
the first expression on the right-hand side of previous display. First notice
that if |d(Tx)| ≤
1
r logx, then
sup
u≤u˜−ǫ
xu−1(φ1(u,d(Tx))− φ0(u,d(Tx)))
= xu˜−ǫ−1(φ1(u˜− ǫ, d(Tx))− φ0(u˜− ǫ, d(Tx))).
Therefore, it suffices to show that the following converges to 0:
P
(
sup
u≤u˜−ǫ
xu−1(Z1(uTx)− φ1(u,d(Tx)))
+ xu˜−ǫ−1(φ1(u˜− ǫ, d(Tx))− φ0(u˜− ǫ, d(Tx)))(7.11)
+ sup
u≤u˜−ǫ
xu−1(φ0(u,d(Tx))−Z
x
0 (uTx))> 0
)
.
To study this let us start by considering the first term in the sum above:
sup
u≤u˜−ǫ
|xu−1(Z1(uTx)− φ1(u,d(Tx)))|
(7.12)
≤ sup
u≤u˜−ǫ
xu(1+λ1/r)−α sup
u≤u˜−ǫ
|xα−λ1u/r−1(Z1(uTx)− φ1(u,d(Tx)))|.
The second term in the product converges to zero in probability via Theo-
rem 3. The first term tends to zero by the following argument:
log
[
sup
u≤u˜−ǫ
xu(1+λ1/r)−α
]
= log[x(u˜−ǫ)(1+λ1/r)−α]
= log
[
x−(1+λ1/r)ǫ−α exp
[
u˜
(
1 +
λ1
r
)
logx
]]
=
(
−α−
(
1 +
λ1
r
)
ǫ
)
logx+
logx
rTx
log
[
1 + xα
(
λ1 + r
µ
)]
≤
(
−α−
(
1 +
λ1
r
)
ǫ
)
logx+
logx
rTx
log
[
2xα
(
λ1 + r
µ
)]
= α
logx
rTx
(logx− rTx)−
(
λ1
r
+1
)
ǫ logx+
logx
rTx
log
[
2(λ1 + 1)
µ
]
,
where in the third equality we have utilized the fact that
u˜
(
λ1 + r
r
)
=
1
rTx
log
[
(λ1 + r)x
α
µ
+ 1
]
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due to the definition of u˜. Observe that −(λ1r +1)ǫ logx diverges to negative
infinity, while the first and third terms approach finite limits. This can be
seen by observing that
logx
rTx
→ 1
in probability. Thus, we conclude that (7.12) goes to zero in probability.
The second term in (7.11) is considered next. Via the definition of φ0(u,
d(Tx)) and the limit result on the extinction time (2.1), we have that as
x→∞,
xu˜−ǫ−1φ0(u˜− ǫ, d(Tx))⇒ c
−(u˜−ε)e−(u˜−ε)η,
where η is a standard Gumbel random variable and c is the positive Yaglom
constant. Importantly, this limit random variable is positive with probability
one. The first term can be shown to approach zero by noting that
xu˜−ǫ−1φ1(u˜− ǫ, d(Tx)) = x
(u˜−ǫ)(1+λ1/r)−αxα−(u˜−ǫ)λ1/r−1φ1(u˜− ǫ, d(Tx)),
where the first term approaches zero, as argued previously since its log
approaches negative infinity, and the product of the remaining terms ap-
proaches a constant times the exponential of a Gumbel, which is again a
result of (2.1). The third term in (7.11),
sup
u≤u˜−ǫ
xu−1(φ0(u,d(Tx))−Z
x
0 (uTx)),
converges to zero in probability by Theorem 3. Therefore,
lim sup
x→∞
P(ξ/Tx ≤ u˜− ǫ)≤ P(c
−(u˜−ε)e−(u˜−ε)η ≤ 0) = 0.
Next, we need to show that P(ξ/Tx ≥ u˜+ ǫ)→ 0. We have by definition
of ξ that
P(ξ/Tx > u˜+ ǫ)≤ P(Z0((u˜+ ǫ)Tx)−Z1((u˜+ ǫ)Tx)> 0)
= P(xα−(u˜+ǫ)(λ1/r)−1(Z0((u˜+ ǫ)Tx)−Z1((u˜+ ǫ)Tx))> 0)
= P(xα−(u˜+ǫ)(λ1/r)−1(Z0((u˜+ ǫ)Tx)− φ0(u˜+ ǫ, d(Tx)))
+ xα−(u˜+ǫ)(λ1/r)−1(φ0(u˜+ ǫ, d(Tx))− φ1(u˜+ ǫ, d(Tx)))
+ xα−(u˜+ǫ)(λ1/r)−1(φ1(u˜+ ǫ, d(Tx))−Z1((u˜+ ǫ)Tx))> 0).
It is easily shown that the right-hand side of the previous display goes to 0
using analogous arguments from the analysis of (7.11).
7.6. Proof of Lemma 4. Here we establish Lemma 4, namely, that u∗(t)
approximates τ/(1r logx+ t).
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Proof. We will prove first that
P
(
inf
u∈[u∗(t)+ε,∞]
Z1(usx(t))<Z0(u
∗(t)sx(t)) +Z1(u
∗(t)sx(t))
)
→ 0.(7.13)
Consider the following decomposition of the event of interest,
P
(
inf
u∈[u∗(t)+ε,∞]
Z1(usx(t))<Z0(u
∗(t)sx(t)) +Z1(u
∗(t)sx(t))
)
≤ P
(
inf
u∈[u∗(t)+ε,∞]
Z1(usx(t))< f(u
∗(t) + ε/2)
)
+ P(Z0(u
∗(t)sx(t)) +Z1(u
∗(t)sx(t))> fx,t(u
∗(t) + ε/2)).
We can apply Markov’s inequality to the last probability to see
P(Z0(u
∗(t)sx(t)) +Z1(u
∗(t)sx(t))> fx,t(u
∗(t) + ε/2))
≤
E[Z0(u
∗(t)sx(t)) +Z1(u
∗(t)sx(t))]
fx,t(u∗(t) + ε/2)
=
fx,t(u
∗(t), t)
fx,t(u∗(t) + ε/2)
=O(x−λ1ε/2r),
where the last equality follows from the “steepness” at the minimum prop-
erty (4.6).
Define the event
Aε(x, t) = inf{Z1(usx(t)) :u ∈ [u
∗(t) + ε,∞)}< f(u∗(t) + ε/2).
Then,
P(Aε(x, t)) = P(Aε(x, t),Z1((u
∗(t) + ε)sx(t))< fx,t(u
∗(t) + 3ε/4))
+ P(Aε(x, t),Z1((u
∗(t) + ε)sx(t))> fx,t(u
∗(t) + 3ε/4))
(7.14)
≤ P(Z1((u
∗(t) + ε)sx(t))< fx,t(u
∗(t) + 3ε/4))
+ P(Aε(x, t),Z1((u
∗(t) + ε)sx(t))> fx,t(u
∗(t) + 3ε/4)).
Using Chebyshev’s inequality and the result in (4.6) again, we see that
P(Z1((u
∗(t) + ε)sx(t))< fx,t(u
∗(t) + 3ε/4))
= P(Z1((u
∗(t) + ε)sx(t))−E[Z1((u
∗(t) + ε)sx(t))]
(7.15)
< fx,t(u
∗(t) + 3ε/4)−E[Z1((u
∗(t) + ε)sx(t))])
≤
E[|Z1((u
∗(t) + ε)sx(t))−EZ1((u
∗(t) + ε)sx(t))|
2]
|fx,t(u∗(t) + 3ǫ/4)− EZ1((u∗(t) + ε)sx(t))|2
.
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Let us consider first the denominator in the above expression, and note that
since u∗(t) minimizes EZ0(usx(t)) + EZ1(usx(t)), we have that
r
λ1
xeλ0u
∗(t)((1/r) log x+t)
(
1−
µ
xα(λ1 + r)
)
=
x1−αµ
λ1 + r
eλ1u
∗(t)((1/r) log x+t).
Thus,
E[Z1((u
∗(t) + ε)sx(t))]
= xeλ0u
∗(t)((1/r) log x+t)
[
−
µ
xα(λ1 + r)
eλ0ε((1/r) logx+t)
+
r
λ1
(
1−
µ
xα(λ1 + r)
)
eλ1ε((1/r) logx+t)
]
.
Also,
fx,t(u
∗(t) + 3ε/4)
= xeλ0u
∗(t)((1/r) log x+t)
(
1−
µ
xα(λ1 + r)
)
(eλ03ε/4((1/r) log x+t)
+ (r/λ1)e
λ13ε/4((1/r) log x+t)),
and therefore∣∣∣∣fx,t
(
u∗(t) +
3ǫ
4
)
− EZ1((u
∗(t) + ε)sx(t))
∣∣∣∣
2
=
∣∣∣∣x1−u∗(t)eλ0u∗(t)t
×
[(
1−
µ
xα(λ1 + r)
)(
x−3ε/4e3λ0εt/4 +
r
λ1
x3λ1ε/4re3λ1εt/4
)
+
µ
xα(λ1 + r)
x−εe−εt −
r
λ1
(
1−
µ
xα(λ1 + r)
)
xλ1ε/reλ1εt
]∣∣∣∣
2
=Ω(x2(λ1ε/r+1−u
∗(t))).
Next we consider the variance term. For ease of notation define θ(t) ≡
(u∗(t) + ε)(1r logx+ t), then from item (iii) of Lemma 1,
Var[Z1((u
∗(t) + ε)sx(t))]
=
(
µ
xα
)2 ∫ θ(t)
0
∫ θ(t)
0
Cov(Z0(s),Z0(y))e
λ1(2θ(t)−s−y) dsdy
+
(
µ
xα
)∫ θ(t)
0
EZ0(s)(2r1e
2λ1(θ(t)−s) − (r1 + d1)e
λ1(θ(t)−s))ds.
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We now establish that Cov(Z0(s),Z0(y)) is an O(x) quantity. Since the
population Z0 starts with x independent cells, we can write the covariance
as
Cov(Z0(s),Z0(y)) = E
[
x∑
j=1
Z
(j)
0 (y)
x∑
i=1
Z
(i)
0 (s)
]
− E[Z0(s)]E[Z0(y)]
= xE1[Z0(s)Z0(y)] + x(x− 1)E1[Z0(s)]E1[Z0(y)]
−E[Z0(s)]E[Z0(y)]
= xCov1(Z0(s),Z0(y)) =O(x).
Based on this we know that the second term in the definition of VarZ1 is the
dominant term and therefore Var[Z1((u
∗(t)+ε)sx(t))] =O(x
1−α+2λ1(u∗(t)+ε)/r).
Then, in order to establish that (7.15) goes to zero it suffices to show that(
1−α+ 2λ1
u∗(t) + ε
r
− 2
(
λ1ε
r
+1− u∗(t)
))
logx→−∞.
The result in the previous display follows from the definition of u∗(t) in
(4.5), and therefore we can conclude that
lim
x→∞
P(Z1((u
∗(t) + ε)sx(t))< fx,t(u
∗(t) + 3ε/4)) = 0.
It remains to show that the final probability in display (7.14) is negligible
for large x. Observe that if we start out with a collection of n independent
cells, each following branching processes with net-growth rate λ1 > 0, then
by the law of large numbers the fraction, fn, of those cells whose lineage
eventually dies out satisfies the following limit: limn→∞ fn = pE(λ1) < 1,
where pE(λ1) is the probability of a single cell’s descendants going extinct
and is strictly less than 1 because λ1 > 0. Therefore, define ρx(u, t) to be the
fraction of type-1 cells present at time u(1r logx+ t) that eventually die out.
Notice then that in order for the event described in the last line of display
(7.14) to occur it is necessary that
ρx(u
∗(t) + ε, t)≥ 1−
fx,t(u
∗(t) + ε/2)
fx,t(u∗(t) + 3ε/4)
.
Then from the “steepness” property we have that, for x sufficiently large,
ρx(u
∗(t)+ ε, t)> pE(λ1)+η, for some η > 0. Of course, from the law of large
numbers we have that
P(ρx(u
∗(t) + ε, t)> pE(λ1) + η,Z1((u
∗(t) + ε)sx(t))> fx,t(u
∗(t) + 3ε/4))
converges to 0 as x→∞, thus establishing (7.13).
Moving on we next establish that
P
(
inf
u∈[0,u∗(t)−ε]
Z0(usx(t))<Z0(u
∗(t)sx(t)) +Z1(u
∗(t)sx(t))
)
→ 0(7.16)
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as x→∞. Note that based on arguments from the above case it suffices to
establish that the following probability converges to 0 as x→∞:
P
(
inf
u∈[0,u∗(t)−ε]
Z0(usx(t))< fx,t(u
∗(t)− ε/2)
)
≤
1
(c0 − 1)fx,t(u∗(t)− ε/2)
× E[(c0fx,t(u
∗(t)− ε/2)−Z0((u
∗(t)− ε)sx(t)))
+]
≤
c0fx,t(u
∗(t)− ε/2)
(c0 − 1)fx,t(u∗(t)− ε/2)
× P(Z0((u
∗(t)− ε)sx(t))< c0fx,t(u
∗(t)− ε/2)),
where we chose c0 > 1, and the penultimate inequality follows from Doob’s
inequality and that −Z0(·sx(t)) is a submartingale. The final probability can
be rewritten as
P(Z0((u
∗(t)− ε)sx(t))− EZ0((u
∗(t)− ε)sx(t))
< c0fx,t(u
∗(t)− ε/2)−EZ0((u
∗(t)− ε)sx(t))).
Note since EZ0((u
∗(t) − ε)sx(t)) = x
1+ε−u∗(t)eλ0t(u
∗(t)−ε) and fx,t(u
∗(t) −
ε/2) = x1+ε/2−u
∗(t)(1 + o(1)), we know that there exists a positive constant
C0 such that for x sufficiently large
EZ0((u
∗(t)− ε)sx(t))− cfx,t(u
∗(t)− ε/2)≥C0x
1+ε−u∗(t),
and therefore for x sufficiently large
P(Z0((u
∗(t)− ε)sx(t))− EZ0((u
∗(t)− ε)sx(t))
< cfx,t(u
∗(t)− ε/2)− EZ0((u
∗(t)− ε)sx(t)))
≤ P(|Z0((u
∗(t)− ε)sx(t))−EZ0((u
∗(t)− ε)sx(t))|>C0x
1+ε−u∗(t)).
Thus, via Chebyshev’s inequality we have
P(|Z0((u
∗(t)− ε)sx(t))−EZ0((u
∗(t)− ε)sx(t))|>C0x
1+ε−u∗(t))
≤
x1/2(Var1Z0((u
∗(t)− ε)sx(t)))
1/2
C0x1+ε−u
∗(t)
=O(x−(1+ε−u∗)/2),
where the final equality follows by evaluating the variance of Z0(u
∗(t)sx(t)). 
7.7. Proof of Lemma 5. As in the proof of the previous lemma, we con-
sider the deviations to the left and right of u∗(t) separately. First, note that
32 J. FOO AND K. LEDER
if t0 > t1, then
inf
u∈[0,u∗(t0)−ε)
Z0
(
u
(
1
r
logx+ t0
))
+Z1
(
u
(
1
r
logx+ t0
))
= inf
{
Z0(s) +Z1(s) : s≤ (u
∗(t0)− ε)
(
1
r
logx+ t0
)}
≥ inf
{
Z0(s) +Z1(s) : s≤ (u
∗(t1)− ε)
(
1
r
logx+ t1
)}
= inf
u∈[0,u∗(t1)−ε)
Z0
(
u
(
1
r
logx+ t1
))
+Z1
(
u
(
1
r
logx+ t1
))
.
Furthermore, it follows from the definition of u∗(t) that Zi(u
∗(t)(1r logx+
t)) =Zi(u
∗(s)(1r logx+ s)) for all s, t. In particular, Zi(u
∗(s)(1r logx+ s)) =
Zi(u
∗Tx). Then via Lemma (4),
P
(
sup
t∈[−M,M ]
inf
u∈[0,u∗(t)−ε)
Z0(usx(t)) +Z1(usx(t))<Z0(u
∗Tx) +Z1(u
∗Tx)
)
converges to zero as x→∞. A similar argument can be used for deviations
to the right of u∗(t) to show that
P
(
sup
t∈[−M,M ]
inf
u∈[u∗(t)+ε,∞)
Z0(usx(t)) +Z1(usx(t))<Z0(u
∗Tx) +Z1(u
∗Tx)
)
also converges to zero as x→∞, establishing the lemma.
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